Xeris Biopharma Holdings
XERS
54 hedge funds and large institutions have $128M invested in Xeris Biopharma Holdings in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 10 reducing their positions, and 8 closing their positions.
9,600% more call options, than puts
Call options by funds: $194K | Put options by funds: $2K
130% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 10
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
2% more funds holding
Funds holding: 53 → 54 (+1)
1.07% less ownership
Funds ownership: 66.37% → 65.31% (-1.1%)
27% less capital invested
Capital invested by funds: $176M → $128M (-$48.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$18.2M |
| 2 |
Blackstone Inc
New York
|
+$3.72M |
| 3 |
DM
Deerfield Management
New York
|
+$2.27M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$2.24M |
| 5 |
Millennium Management
New York
|
+$644K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$39.8M |
| 2 |
EGM
Engineers Gate Manager
New York
|
-$199K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$197K |
| 4 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
-$138K |
| 5 |
JG
Jefferies Group
New York
|
-$115K |
XERS Hedge Fund Activity: Q4 2019 in Review
54 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q4 2019, worth a combined $128M — down 27% from $176M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new XERS positions and 8 closed out — a net gain of 1 holder — while 23 added to existing stakes and 10 trimmed.
The largest buyer was Citigroup, adding an estimated $18.2M. The largest seller was Fidelity Investments, exiting entirely with an estimated $39.8M sold.
- 54 institutional investors held Xeris Biopharma Holdings (XERS) as of Q4 2019, up from 53 in Q3 2019.
- Funds reported $128M of Xeris Biopharma Holdings stock for Q4 2019, down 27% quarter-over-quarter.
- 9 funds opened new Xeris Biopharma Holdings positions in Q4 2019 and 8 closed out, a net change of +1 holder.
- The largest Xeris Biopharma Holdings buyer in Q4 2019 was Citigroup, an estimated $18.2M added.
- The largest Xeris Biopharma Holdings seller in Q4 2019 was Fidelity Investments, an estimated $39.8M sold.
Based on aggregated 13F filings for Q4 2019.